Group 1 - The stock of Haocen Medical reached a closing price of 3.56 yuan on August 12, with a limit-up performance and a closing order fund of 89.68 million yuan, accounting for 3.0% of its market capitalization [1] - The growth in the oral medical business is significant, with Delun Medical's sales revenue expected to increase by 13.94% year-on-year in 2024, indicating a strong expansion trend [1] - The company has improved its operational efficiency, with net profit losses narrowing by 60.06% year-on-year in 2024, signaling positive developments [1] Group 2 - Research and development expenses are projected to surge by 163% year-on-year in Q1 2025, reinforcing the company's strategic investments to enhance long-term competitiveness [1] - A new outpatient clinic in Zhaoqing is set to open in May 2025, along with the expansion of several medical facilities, increasing the number of dental chairs by over 100, thereby enhancing service capacity [1] - The company secured a 113.2 million yuan working capital loan, alleviating short-term financial pressures [1]

Group 1 - The core viewpoint of the news is that Haocen Medical experienced a significant stock price increase, reaching a limit up of 9.88% on August 12, with a trading price of 3.56 yuan per share and a total market capitalization of 2.99 billion yuan [1] - Haocen Medical is primarily engaged in oral medical services and industrial manufacturing, with a focus on the research and innovation of permanent magnet switch products [1] - The company was listed on the Shenzhen Stock Exchange in 2011 under the stock code 002622 and acquired a controlling stake in Guangdong Delun Medical Group Co., Ltd. in 2021 [1] Group 2 - As of March 31, Haocen Medical had 54,000 shareholders, with an average of 15,500 circulating shares per shareholder [2] - For the first quarter of 2025, Haocen Medical reported operating revenue of 143 million yuan, a year-on-year decrease of 12.58%, and a net profit attributable to shareholders of -12.21 million yuan, a year-on-year decrease of 167.13% [2]

Company Performance - As of August 6, 2025, Haocen Medical (002622) closed at 3.04 yuan, down 1.62% with a trading volume of 193,900 hands and a transaction amount of 59.17 million yuan [1] - The company's main business includes oral medical services and the research, production, and sales of permanent magnet switches and high/low voltage switchgear [2] Financial Metrics - Total market value of Haocen Medical is 2.55 billion yuan, significantly lower than the industry average of 19.63 billion yuan, ranking 41st out of 42 in the industry [2] - The net profit for the company is -12.21 million yuan, a decline of 167.13% year-on-year, with a net profit margin of -12.6%, ranking 36th out of 42 [2] - The company's gross profit margin stands at 38.5%, which is above the industry average of 34.85%, ranking 18th out of 42 [2] Recent Trading Activity - On August 6, 2025, the net outflow of main funds was 3.88 million yuan, accounting for 6.56% of the total transaction amount, while retail funds saw a net inflow of 5.88 million yuan, making up 9.94% of the total [1] - Over the past five days, the stock has experienced fluctuations in fund flows, with notable net outflows from main funds on multiple days [1]

Group 1 - The company expects a net loss for the period from January 1, 2025, to June 30, 2025, with projected losses ranging from 28 million to 20 million yuan, compared to a profit of 0.5535 million yuan in the same period last year [1] - The expected net profit attributable to shareholders, after deducting non-recurring gains and losses, is projected to be a loss between 26 million and 19 million yuan, compared to a profit of 1.691 million yuan in the previous year [1] - Basic earnings per share are expected to be a loss between 0.0333 yuan and 0.0238 yuan, compared to earnings of 0.0007 yuan per share in the same period last year [1] Group 2 - The performance forecast has not been audited by registered accountants [1] - The decline in performance is attributed to intensified market competition in the oral medical service sector, increased customer acquisition costs, and a decrease in average transaction prices for similar products, leading to reduced profits [1] - Additionally, the company's investment income has decreased due to a decline in the valuation of financial products from its associate, Fushun Bank Co., Ltd., contributing to the overall loss for the first half of 2025 [1]

[Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates a significant shift from profit to loss in the first half of 2025, with net profit attributable to shareholders projected to be a substantial loss compared to the prior year's profit Key Financial Performance Indicators | Item | Current Period | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | Loss: 28.00 million - 20.00 million yuan | Profit: 0.5535 million yuan | | **Net Profit After Non-Recurring Items** | Loss: 26.00 million - 19.00 million yuan | Profit: 0.1691 million yuan | | **Basic Earnings Per Share** | Loss: 0.0333 - 0.0238 yuan/share | Profit: 0.0007 yuan/share | [Pre-Audit Status of Performance Forecast](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E9%A2%84%E5%AE%A1%E8%AE%A1%E6%83%85%E5%86%B5) The performance forecast data has not been pre-audited by a certified public accountant and represents preliminary estimates by the company's finance department - This performance forecast has not been pre-audited by a certified public accountant[4](index=4&type=chunk) [Explanation of Performance Change](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The H1 2025 loss is primarily due to declining profitability in core dental medical services and reduced investment income from the associated company, Fushun Bank - Core business challenges include increased market competition, rising customer acquisition costs, and declining average transaction value in dental medical services, leading to reduced profitability[5](index=5&type=chunk) - Decreased investment income from the associated company, Fushun Bank, due to a decline in the valuation of its financial product investments, is another significant factor contributing to the loss[5](index=5&type=chunk) [Other Relevant Information](index=1&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company states that the forecast data is preliminary, with final financial figures subject to the official H1 2025 semi-annual report, and advises investors to be aware of investment risks - The forecast data is preliminary, and the definitive financial figures will be based on the company's officially disclosed 2025 semi-annual report[6](index=6&type=chunk) - The company will timely disclose information as required and reminds investors to be mindful of investment risks[7](index=7&type=chunk)

Group 1 - The company held its 24th temporary meeting of the 5th board of directors on July 7, 2025, with all 7 directors present, ensuring compliance with relevant laws and regulations [1] - The board approved a proposal to apply for a loan renewal from Shanxi Bank for an amount not exceeding RMB 113.2 million, aimed at meeting operational liquidity needs [2] - The company's wholly-owned subsidiaries, Jilin Yongda Electric Switch Co., Ltd. and Beijing Rongyu Technology Co., Ltd., will provide collateral for the loan with their property rights, while the company will pledge 20% of its shares in Beijing Wantai Zhonglian Technology Co., Ltd. as additional security [2] Group 2 - The board authorized the chairman or their representative to sign relevant agreements and handle matters related to the loan renewal [2] - The announcement regarding the loan renewal and subsidiary guarantees will be disclosed in designated media outlets [2]

Transaction Overview - The company plans to apply for a one-year loan renewal from Shanxi Bank, with an amount not exceeding RMB 113.2 million to meet operational funding needs [1][3] - The loan will be secured by the company's wholly-owned subsidiaries, Jilin Yongda Electric Switch Co., Ltd. and Beijing Rongyu Technology Co., Ltd., providing mortgage guarantees on their property and land use rights [1][3] - The company will also pledge 20% of its shares in Beijing Wantai Zhonglian Technology Co., Ltd. as collateral for the loan [1][3] Counterparty Information - Shanxi Bank is a non-listed joint-stock company established on April 27, 2021, with a registered capital of approximately RMB 258.94 million [2] Guarantee Agreement Details - The guarantee for the loan includes collateral from the subsidiaries and a pledge of shares, with additional joint liability guarantees from subsidiaries Zhiyu Medical Investment Co., Ltd. and Beijing Lulubai Technology Co., Ltd. [1][2][3] Board of Directors' Opinion - The board supports the loan application as it is essential for the company's operational development and liquidity needs [3] External Guarantee Amount - As of the announcement date, the total external guarantee amount by the company and its subsidiaries is RMB 77.9 million, accounting for 19.57% of the audited net assets for 2024 [3]

关于拟向银行申请续贷并由子公司提供担保的公告 证券代码：002622 证券简称：皓宸医疗 公告编号：2025-016 皓宸医疗科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 为满足皓宸医疗科技股份有限公司（以下简称"公司"）经营发展需要，补 充公司日常运营所需流动资金，公司拟向山西银行股份有限公司申请期限为一年 的续贷业务，金额不超过人民币 1.132 亿元，由公司全资子公司吉林永大电气开 关有限公司及北京融钰科技有限公司以其合法持有的房屋所有权及土地使用权 提供抵押担保，公司以持有的北京万泰中联科技股份有限公司 20%股权进行质押 为本次续贷业务提供担保，公司全资子公司植钰医疗投资有限公司及北京陆陆捌 科技有限公司为本次续贷业务提供连带责任保证。 公司已于 2025 年 7 月 7 日召开第五届董事会第二十四次临时会议审议通过 上述事项，董事会授权董事长或其授权代表签署相关协议及办理续贷有关事项。 根据相关法律法规及《公司章程》的有关规定，上述事项不属于关联交易，在董 事会审批权限内，无需提交股东大会审议。 二、交易对方基本情 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-015 皓宸医疗科技股份有限公司 第五届董事会第二十四次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届董事会第二十四次 临时会议于 2025 年 7 月 7 日下午 14:30 以现场结合通讯表决的方式召开。本次 会议已于 2025 年 7 月 3 日以电话、电子邮件等方式通知了各位董事。本次会议 由董事长陆璐女士主持，会议应出席董事 7 名，实际出席董事 7 名。此次会议的 召集、召开与表决程序符合《中华人民共和国公司法》和《公司章程》及相关法 律、法规的规定，合法有效。经与会董事认真审议并表决，通过了以下议案： 一、审议通过《关于拟向银行申请续贷并由子公司提供担保的议案》 表决情况：同意 6 票，反对 0 票，弃权 1 票（董事蔡惠燕女士投弃权票，弃 权理由：因所在单位内部决策未形成统一意见，对本次会议议案不参与表决）； 为满足经营发展需要，补充公司日常运营所需流动资金，董事会同意公司向 山西银行股份有限公司申请期限为一年的 ...

Market Overview - The Shanghai Composite Index closed at 3399.77 points, above the six-month moving average, with a gain of 0.43% [1] - The total trading volume of A-shares reached 13126.55 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 220 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 8.76% deviation, closing price at 14.00 yuan, with a daily gain of 16.86% and turnover rate of 21.88% [1] - Haochen Medical: 8.62% deviation, closing price at 3.12 yuan, with a daily gain of 9.86% and turnover rate of 7.25% [1] - Guangyun Technology: 8.13% deviation, closing price at 14.22 yuan, with a daily gain of 9.89% and turnover rate of 6.59% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - CITIC Special Steel: minor deviation, closing price at 20.30 yuan, with a daily gain of 10.69% [1] - Nanda Optoelectronics: minor deviation, closing price at 36.44 yuan, with a daily gain of 9.99% [1] -沃尔核材: minor deviation, closing price at 25.41 yuan, with a daily gain of 11.75% [1]